President Donald Trump disclosed stock purchases worth as much as $680,000 in Eli Lilly & Co. (NYSE:LLY) earlier this year, with the trades occurring as federal agencies under his administration advanced policies that benefited the drugmaker's obesity drug business.
Trump's Eli Lilly Purchases Coincided With GLP-1 Policy Developments
Something went wrong.
Citing disclosure forms signed by Trump, KFF Health News reported seven purchases of Eli Lilly shares through the end of March. The first transaction occurred on January 6, according to the filings.
The company, valued at nearly $1 trillion by the market, has become a major player in the growing GLP-1 weight-loss drug market.
